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Background. T cell mediated inflammation contributes to atherogenesis and the onset of acute cardiovascular disease.
Effector T cell functions are under a tight control of a specialized T cell subset, regulatory T cells (Treg). At present, nothing is
known about the in situ presence of Treg in human atherosclerotic tissue. In the present study we investigated the frequency
of naturally occurring Treg cells in all developmental stages of human atherosclerotic lesions including complicated
thrombosed plaques. Methodology. Normal arteries, early lesions (American Heart Association classification types I, II, and III),
fibrosclerotic plaques (types Vb and Vc) and ‘high risk’ plaques (types IV, Va and VI) were obtained at surgery and autopsy.
Serial sections were immunostained for markers specific for regulatory T cells (FOXP3 and GITR) and the frequency of these
cells was expressed as a percentage of the total numbers of CD3
+ T cells. Results were compared with Treg counts in biopsies
of normal and inflammatory skin lesions (psoriasis, spongiotic dermatitis and lichen planus). Principle findings. In normal
vessel fragments T cells were virtually absent. Treg were present in the intima during all stages of plaque development (0.5–
5%). Also in the adventitia of atherosclerotic vessels Treg were encountered, in similar low amounts. High risk lesions
contained significantly increased numbers of Treg compared to early lesions (mean: 3.9 and 1.2%, respectively). The frequency
of FOXP3
+ cells in high risk lesions was also higher compared to stable lesions (1.7%), but this difference was not significant.
The mean numbers of intimal FOXP3 positive cells in atherosclerotic lesions (2.4%) was much lower than those in normal
(24.3%) or inflammatory skin lesions (28%). Conclusion. Low frequencies of Treg in all developmental stages of human plaque
formation could explain the smoldering chronic inflammatory process that takes place throughout the longstanding course of
atherosclerosis.
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INTRODUCTION
A chronic, T cell mediated inflammatory process determines the
growth and development of atherosclerotic lesions [1–3]. Although
the majority of the inflammatory cells in atherosclerotic lesions are
macrophages, up to 20 percent of the cells are T lymphocytes
[2,4]. Moreover, activation of T cells is considered to play an
important role in the process of atherosclerotic plaque de-
stabilization which may initiate plaque disruption and the onset
of acute coronary syndromes[5–7]
In general, the effector functions of activated T cells are under
tight control of a special subset of T cells, the regulatory T cells
(Treg). Treg play a central role in inducing and maintaining
immunologic tolerance and the termination of immune responses.
Deficiency or dysfunction of these cells lead to autoimmunity or
aggravated pathogen-induced inflammation[8,9]. An important
population of Treg is formed by the naturally occurring Treg,
phenotypically characterized by a high constitutive expression of
CD25, the alpha chain of the interleukin-2 receptor, and also
referred to as CD4
+CD25
+ regulatory T cells[10]. In tissues these
cells are best identified by their expression of transcription factor
FOXP3 (Forkhead Box Protein P3), a member of the forkhead
winged helix protein family of transcription factors[11].
Since atherosclerotic plaque inflammation also relates to
autoimmunity, likely induced by oxidized LDL epitopes [12],
a role for Treg in atherosclerotic inflammatory process could be
anticipated. Indeed, experimental studies have shown that
adoptive transfer of Treg prevent the development of plaques in
mouse models of atherosclerosis[13–15]. Furthermore, it was
recently shown that the numbers of Treg are decreased in the
peripheral blood of patients with acute coronary syndromes[16].
However, the in situ presence of Treg in human atherosclerotic
plaques has not yet been investigated.
In the present study we systematically evaluated the distribution
of regulatory T cells in all developmental stages of human plaques
(type 1 to VI according to the classification of the American Heart
Association, AHA) with the use of monoclonal antibodies against
regulatory T cell markers FOXP3 and GITR. Cellular specificity
of FOXP3 and GITR for T cells was investigated with immuno-
doublestains visualized with spectral imaging [17]. Moreover,
using the AHA classification of lesions, we compared specifically
the relative frequency of Treg in early, stable, and high risk
(vulnerable and thrombosed) plaques. In order to get insight in the
numbers of Treg that participated in atherosclerosis, we compared
these data with the Treg counts in normal human skin and in the
inflammatory infiltrates encountered in various types of T cell
mediated inflammatory skin diseases.
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Specimens
Atherosclerotic vessel fragments were collected from 42 patients
undergoing vascular surgical interventions and from 3 patients at
autopsy (mean age: 62.1 years69.5). A total of 69 different
diseased vessel fragments were studied from the aorta (n=26),
a.carotis (n=32, all endarterectomies), and a.femoralis (n=11). All
specimens were formalin fixed and paraffin embedded. After
preparation of hematoxylin-eosin and Elastic van Gieson stained
sections, plaques were categorized according to the American
Heart Association classification of atherosclerotic lesions[18]:
type1: initial lesion (n=7); type II, fatty streak (n=10); type III,
proatheroma (n=7); type IV, atheroma (n=7); type Va,
fibroatheroma (n=9); type Vb, calcified plaque (n=8), type Vc,
fibrotic plaque (n=9) and type VI, complicated plaques (plaques
with thrombus formation or intraplaque hemorrhage, n=12). For
additional comparisons in the present study, these lesions were
pooled into 3 groups: early lesions (AHA type I, II, and III);
fibrosclerotic lesions (stable plaques, AHA type Vb and Vc) and
‘high risk’ plaques (vulnerable and thrombosed plaques, AHA type
IV, Va and VI).
As reference materials we used segments of mammary arteries,
which are known to be relatively resistant to the development of
atherosclerotic plaques. The segments were obtained from 10
patients (mean age: 65.2 years69.7) undergoing coronary artery
bypass surgery, in which mammary artery was used in the bypass
graft, and the remainder of the artery was send to the pathology
lab. Of these, 36 cross sectional segments were collected, which
showed a normal arterial wall (n=30) or early atherosclerotic
lesions (AHA type 1 (n=5) and AHA type 2 (n=1)).
Frequencies calculated from atherosclerotic tissue were com-
pared with a similar study performed on normal and inflamed skin
specimens, performed using identical methods and techniques
[17]. In that study distribution of Treg was investigated on T cells
in normal human skin (n=14), psoriatic skin (n=13), spongiotic
dermatitis (n=13) and lichen planus (n=12).
Tissue samples used in this study were from the ‘‘AMC-
vesselbank’’, a collection of well documented vessel fragments
obtained after vascular surgical interventions or autopsy[19,20],
and oral informed consent was obtained from all participants or
relatives included in this study. Acquisition of tissue samples was
approved by the institutional medical ethical committee and the
study was conducted according to the Declaration of Helsinki
Principles.
Immunohistochemistry
Immunohistochemical single and double stains were performed on
5 mm thick sections prepared from formalin fixed, paraffin
embedded tissue, as previously described [17]. The following
antibodies were used: rabbit monoclonal anti CD3 (SP7,
Labvision, Freemont, CA), mouse monoclonal anti FOXP3 (clone
236A/E7; Abcam, Cambridge, UK), goat polyclonal anti-GITR
(R&D Systems Europe Ltd), mouse monoclonal anti CD20
(Labvision), mouse monoclonal anti CD68 (PGM1, Dako) and
mouse monoclonal anti CD138 (Dako). As a second step the
following reagents were used: Rabbit anti-goat (Dako), Poly-AP
anti-mouse (Immunovision Technologies, Brisbane, USA) and
Envision+anti-rabbit (Dako). As chromogens we used DAB+ and
Liquid Permanent Red Kit (both from Dako). Spectral imaging,
a computer assisted optical technique allowing a detailed analysis
of double stained cells was performed as previously described[17].
Quantification Quantification of FOXP3 and GITR positive
T cells in atherosclerotic tissue was performed in single-stained
serial sections. The centre section was stained for CD3, whereas
the two adjacent sections were stained for FOXP3 and GITR,
respectively. Frequency of FOXP3 and GITR positive cells were
determined by taking a digital overview image of each CD3-
stained section at a low power magnification (1062). In each of
these images 4 areas in the region of interest (intima or adventitia)
with the highest density of CD3 positive cells were manually
marked, using image analysis software (Image Pro Plus, vs. 5.01,
Media Cybernetics, Silver Spring, MD). Next, these selected areas
were retraced at high power (10620) magnification and in each set
of adjacent GITR, CD3, and FOXP3-stained sections digital
images were captured of these spots. The total numbers of positive
cells in interrelated images were counted using the ‘‘manual tag’’
option of Image Pro Plus, and the numbers of GITR and FOXP3
positive cells were expressed as percentage of CD3 positive cells.
Statistical analysis Statistical differences between the
different inflammatory conditions were evaluated by One way
Anova, followed by post-hoc Tukey test. P,0.05 was considered
statistically significant. Statistical analysis was performed using the
SPSS software package (Chicago, IL, USA, vs. 11.5 for Windows).
RESULTS
1. Distribution of CD3, FOXP3, and GITR in normal
human vessel fragments and atherosclerotic tissue
First, we investigated the distribution of T cells and Tregs in
normal human vessel fragments. Thirty different control vessel
fragments from the mammary artery, a vessel know to be relatively
resistant for the development of atherosclerotic plaques were
studied. T cells were virtually absent in the normal arterial intima:
in the 30 specimens of mammary arteries we investigated, a total
of 22, scattered T cells were encountered. Similar low counts of T
cells were found in the adventitial tissue surrounding normal vessel
fragments. On average, approximately 1.4 T cell/mm
2 was
encountered. In none of the specimens FOXP3 or GITR positive
cells were encountered. Figure 1 shows a representative example of
a normal mammary artery, stained with H&E (A) and CD3 (B).
Representative histological examples of the intima of athero-
sclerotic vessels, i.e an early lesion (AHA class II), an advanced
lesion (AHA class Va) and a recently thrombosed plaque (AHA
class VI) are illustrated in Figure 2, where sections stained with
hematoxylin&eosin, CD3, FOXP3, and GITR are shown. CD3
positive T cells were found in the intima in lesions from all stages
of plaque development. The numbers of CD3 positive T cells
increased with the plaque severity. FOXP3 and GITR positive
cells were observed in the intima in all stages of plaque
development but their numbers were, compared to CD3 very low.
In 29 of the specimens (13 early-, 4 fibrosclerotic-and 11 high
risk plaques) adventitial tissue was present which could be studied
Figure 1. Histology of normal human artery. Hematoxylin&eosin
overview (A, bar=200 mm) and detailed CD3 (B, bar=50 mm) staining
of a normal human (mammary) artery. CD3 positive T cells are rare in
normal human intima.
doi:10.1371/journal.pone.0000779.g001
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which were composed of T cells, B cells, macrophages and plasma
cells.FOXP3andGITRpositivecellswerealsoencounteredinthese
specimens but, similar to atherosclerotic intima, their numbers were
low. However, focal accumulations of GITR expressing cells were
observed in 4 high risk plaques. This was typically the case in those
specimens with follicular lymphoid infiltrates, which are known to be
associated with advanced atherosclerosis.
Immunodoublestains were performed to verify the phenotype
of the FOXP3
+ and GITR
+ cells in atherosclerotic tissue. In
atherosclerotic intima, FOXP3
+-and GITR
+ cells were always
CD3 positive (see figure 3A and B for representative examples),
indicating that all these FOXP3 and GITR positive cells are T
cells. In atherosclerotic adventitia FOXP3 was always co-
expressed with CD3. However, GITR positive cells in the
lymphoid adventitial infiltrates in some high risk plaques were
not only T cells, but additionally CD138
+ plasma cells were GITR
positive (fig 3D). CD20
+ B cells and CD68
+ macrophages were
GITR negative (Figure 3D and 3F, respectively).
2. Frequency of FOXP3 and GITR in atherosclerotic
intima
After having assessed that all FOXP3 and GITR positive T cells in
atherosclerotic intima are indeed T cells, we counted the numbers
of CD3, FOXP3 and GITR positive T cells and expressed the
numbers of FOXP3 and GITR positive cells in these lesions as
a percentage of the total number of T cells (figure 4A). The
frequency of FOXP3 positive T cells varied from 0.5% in AHA
class I-to 5% in class VI lesions. Using the AHA classification, we
found no significant differences between the different groups.
However, when comparing ‘high risk’ lesions with early lesions, we
observed that the frequency of FOXP3 positive cells T cells was
significantly increased from 1.2 to 3.9.% (Figure 4C). The
frequency of FOXP3 positive T cells in advanced lipid rich
lesions was also higher compared fibrosclerotic plaques (3.9 vs
1.7%), but this difference was just not significant (p=0.06).
The mean frequency of GITR positive cells is illustrated in
Figure 4B. The mean frequency of intimal GITR positive T cells
was in the range of 2.3 (AHA Vc) to 4.3% (AHA II). No significant
difference in the frequency of GITR positive T cells between the
different types of lesions was found (Figures 4B and 4D).
3. Frequency of FOXP3
+ and GITR
+ cells compared
with atherosclerotic adventitia, normal and
inflammatory skin
Knowing the frequency of FOXP3 and GITR positive cells in
atherosclerotic intima, we next wanted to know the frequency of
these cells in the adventitia, and under inflammatory conditions in
a different tissue. Figure 5A shows that the mean frequency of
FOXP3 positive T cells in atherosclerotic intima and adventitia
Figure 2. Histology of different types of atherosclerotic arteries. Hematoxylin&Eosin overview (A, E, I, bar=200 mm) and detailed CD3 (B, F, J,
bar=50 mm), FOXP3(C, G, K) and GITR(D, H, L) stains of three different types of atherosclerotic lesions: AHA class II (A–D), AHA class Va (E–H) and AHA
class VI (I–L). CD3 positive T cells are frequently present in atherosclerotic tissue, but Treg are scarce.
doi:10.1371/journal.pone.0000779.g002
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of FOXP3 positive T cells in normal, as well as in inflammatory skin
lesions was significantly higher, 24 and 28%, respectively. Similar
results were observed with GITR (figure 5B): the frequency of GITR
positive cells was significantly higher in normal and inflammatory
skin lesions compared to atherosclerotic intima.
DISCUSSION
Regulatory T cells play a central role in inducing and maintaining
immunologic tolerance and the termination of immune responses,
and deficiency or dysfunction of these cells lead to autoimmunity
or aggravated pathogen-induced inflammation[8,9]. Also in
atherosclerotic disease the presence and function of regulatory T
cells may have important implications, because of their potential
suppressive effects on the in situ inflammatory response. In the
present study we investigated the presence of naturally occurring
regulatory T cells in normal and atherosclerotic vessels by studying
the presence of FOXP3 and GITR positive T cells. In normal
intima T cells are virtually absent. T cells and Treg are present in
atherosclerotic plaques, but the frequency of the latter is low
(0.5–5%). Despite these relatively low numbers, related to the total
number of T cells present in the plaque, we found that high risk
plaques (AHA IV, Va and VI) contain significantly more FOXP3
positive T cells compared to early lesions (AHA 1, II and III). It is
known that the onset of acute coronary syndromes is associated
with changes in the inflammatory response in these lesions,
including a shift in phenotype of intraplaque T cells: the frequency
of activated T lymphocytes is significantly increased in unstable
lesions [5,21]. Furthermore, it is has been shown that the onset of
acute coronary syndromes is associated with the antigen driven,
oligoclonal proliferation of certain T cell subsets[6]. It appears that
as a result of such an increase in T cell mediated inflammatory
activity, also the frequency of Treg increases in these unstable
lesions.
At present, most studies on Treg in relation to (auto) immunity
have been performed on peripheral blood Treg. Peripheral blood
Treg are relatively easily detectable by their high constitutive
expression of CD25 (CD4
+CD25
high subset). In humans, de-
creased frequency of peripheral blood CD4
+CD25
high Treg have
been linked to different types of autoimmune diseases like
rheumatoid arthritis, type-1 diabetes, multiple sclerosis and
systemic lupus erythematosus [22–25]. Recently it was shown
that the frequency of Treg is also decreased in the peripheral blood
Figure 3. Double staining images after spectral imaging. A: FOXP3 (green) and CD3 (red) in atherosclerotic intima. Nuclei are depicted in blue. Inset
shows double stained cell. Note nuclear staining of transcription factor FOXP3 and cytoplasmatic CD3 positivity; B: GITR (green) and CD3 (red) in
atherosclerotic intima. Inset shows one double and one single stained cell; C: GITR (green) and CD3 (red) in atherosclerotic adventitia. GITR positive
cells do not co-express CD3. D: GITR (green) and CD20 (red). No double stained cells. E: GITR (green) and CD138 (red). Inset shows double stained
cells. F: GITR (green) and CD68 (red). No double stained cells.
doi:10.1371/journal.pone.0000779.g003
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first describing (low numbers) of Treg also inside human plaques.
In the present study we used FOXP3 and GITR to analyze the
presence of Treg in situ. GITR is directly involved in maintaining
immunological tolerance by GITR-GITRligand interactions
[27,28]. However, recently activated T lymphocytes may also
express GITR, and therefore the expression of GITR by T
lymphocytes should be taken with caution. Still, in the present
study we found that, apart from the adventitia in advanced
atherosclerotic plaques, the distribution of GITR and FOXP3
were comparable, and the results obtained with GITR were in line
with the observations obtained with FOXP3. Transcription factor
Figure 4. Frequency of FOXP3 and GITR positive T cells in atherosclerotic tissue. Values are expressed as a percentage (6SD) of the total number
of T lymphocytes. Plaques were categorized according to the AHA classification (A and B, respectively) or categorized as early, fibrosclerotic and
vulnerable lesions (C and D, respectively). *: P,0.05
doi:10.1371/journal.pone.0000779.g004
Figure 5. Treg in atherosclerotic tissue compared to normal skin and inflammatory dermatoses. Frequency of FOXP3 (A) and GITR (B) positive T
cells in atherosclerotic and dermal specimens. Values are expressed as percentage (6SD) of the total number of T lymphocytes. The frequency of Treg
in atherosclerotic intima and adventitia are significantly lower compared to both normal skin as well as a panel of inflammatory dermatoses (psoriasis,
spongiotic dermatitis and lichen planus). **: P,0.005
doi:10.1371/journal.pone.0000779.g005
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identify naturally occurring Treg in situ [17,29,30]. Only recently
reliable monoclonal antibodies specific for FOXP3 became
available[31], and therefore there are not many data available
yet on the distribution or frequency of Treg in solid tissues. In the
present study we observed that the mean frequency of FOXP3
positive Treg in atherosclerotic intima, but also in atherosclerotic
adventitia was in the range of the 0.5–5% of the total number of
CD3 positive T cells. By contrast, in a previous study [17],
performed under identical methodological conditions, we found
that the frequency of FOXP3 positive T cells in normal skin and
a panel of inflammatory skin diseases was in the range of 25–30%,
which is significantly higher compared to the situation in
atherosclerotic intima and adventitia. It thus appears that, at least
compared to normal and various T cell mediated inflammatory
skin diseases, the frequency of Treg in atherosclerotic tissue is very
low. This raises two important questions: first, what the reason for
this low frequency of Treg in atherosclerotic tissue, and the
second, does this have biological and/or clinical implications.
Recently, it was shown that oxidized lipoproteins inhibited
FOXP3 expression and Treg function of mouse effector cells in
vitro[15]. Thus, it could be that oxidized lipids, present already in
the intima in the earliest stages of atherosclerosis, locally inhibit
FOXP3 expression and Treg function in vivo. Indeed, we found
that the frequency of Treg is not only relatively low in advanced,
but also in early lesions. Similarly, the low frequency of FOXP3
+
Treg in the adventitia could be the result of plaque derived
lipoproteins, transported via Vasa vasorum microvessels to the
adventitia. On the other hand, it is also possible that other
mechanisms are responsible for the low numbers of Treg, like
a decreased homing of Treg into vascular tissue. Still, it also
important to note the frequency of Treg may be highly variable
between different solid tissues, and so far we only compared
(inflammatory) skin and atherosclerotic vessels.
The second important question that should be addressed
concerns the biological and clinical implications of this low
frequency of Treg in atherosclerotic tissue. In this respect it is first
important to emphasize again that both experimental, as well as
studies in humans have clearly shown that T cells and T cell
activation are very important in development of atherosclerotic
lesions, and the onset of acute cardiovascular syndromes [32].
Furthermore, it has been shown that increasing the numbers of
Treg in atherosclerosis prone (ApoE-/-) mice by means of adoptive
transfer leads to smaller atherosclerotic lesions[13–15], implicating
that Treg do appear capable modifying plaque volume in vivo.
These observations, taken together with the findings on the in situ
expression of Treg in human plaques of the present study make it
tempting to speculate that such low umber of Treg do have
implications could be explain the smoldering chronic inflamma-
tory process in the longstanding course of atherosclerosis.
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